Clinical trials: Liver Biomarkers
Liver Transplantation
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g.
- Trial name
- NCT02736227
- Testing
- Tacrolimus Withdrawal and Everolimus Monotherapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Chronic Kidney Disease, Chronic Hepatitis C
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
- Trial name
- NCT02946034
- Testing
- Viekira Pak ± ribavirin, Mavyret
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a…
- Trial name
- NEXSCOT (NCT04147195)
- Testing
- LYS006, Tropifexor
- Where
- 10 sites in United States, Argentina and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
- Trial name
- BARI (NCT03294850)
- Testing
- Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Cardiovascular Disease, Hypercholesterolemia
Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol
The purpose of this study is to investigate the short-term effects of a reduced fat plant-based diet on biomarkers of inflammation, oxidative stress and cardiovascular risk.
- Conditions
- Cardiovascular Disease, Hypercholesterolemia, Obesity, Fatty Liver
- Trial name
- NCT01817491
- Testing
- American Heart Association Diet, Reduced Fat Vegan Diet
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Nonalcoholic Fatty Liver Disease (NAFLD)
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty…
- Trial name
- NCT02244944
- Testing
- EZ-Urso combination therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gregory Graf, PhD
Single Ventricle Heart Disease
Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness
A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.
- Trial name
- FALD (NCT03430583)
- Testing
- Udenafil
- Where
- 17 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Mezzion Pharma Co. Ltd
Hepatocellular Carcinoma
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
The purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT01521780
- Testing
- MRI, Pathology, Blood Samples
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cancer
Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
The purpose of this study is to determine the whether Lipiodol can be used as an imaging biomarker, predicting tumor response to therapy in patients with primary and metastatic liver cancer.
- Trial name
- NCT01877187
- Testing
- Lipiodol
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Noninvasive Biomarkers of Metabolic Liver Disease 1.1
NIMBLE is a comprehensive collaborative effort to standardize, compare, validate, and advance the regulatory qualification of imaging and circulating biomarkers to diagnose and stage nonalcoholic steatohepatitis (NASH), and to…
- Trial name
- NCT04828551
- Testing
- Ultrasound based shear wave speed and fat quantification methods, Blood collection, Physical measurements
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Liver Diseases, Liver Cancer
Breath Analysis Based Disease Biomarkers
The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
- Conditions
- Liver Diseases, Liver Cancer, COVID19
- Trial name
- NCT04341012
- Testing
- Collection of breath sample
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Non-Alcoholic Fatty Liver Disease
Investigation of Synbiotic Treatment in NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver condition in which fat builds up in the liver not caused by alcohol. The liver is an organ that is not designed to build up fat.
- Trial name
- INSYTE (NCT01680640)
- Testing
- Synbiotic, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Non-Alcoholic Fatty Liver Disease
Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management.
- Trial name
- WELCOME (NCT00760513)
- Testing
- OMACOR
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Solid Tumor
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR…
- Trial name
- NCT01752920
- Testing
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range
- Where
- 12 sites in United States, Italy
- Volunteers
- 119 people
- Sponsor
- Basilea Pharmaceutica
Hepatitis B, Chronic
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
This Phase 4 study is designed for the collection of blood biomarker samples from participants who have completed CHB treatment with at least 24 weeks of a pegylated interferon alfa-2a (Peg-IFN alfa-2a) containing regimen and at…
- Trial name
- NCT01855997
- Testing
- Peg-IFN alfa-2a
- Where
- 84 sites in Austria, Bulgaria and 13 more
- Volunteers
- 1,669 people
- Sponsor
- Hoffmann-La Roche
Nonalcoholic Fatty Liver Disease (NAFLD)
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease
This study will advance several goals of the NIH Action Plan: 1) establish a multidisciplinary team to develop quantitative methodologies and imaging protocols for liver, 2) validate diagnostic criteria and methodologies for…
- Trial name
- NCT01930123
- Testing
- intravenous fructose challenge, Blood Draw
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Manal F Abdelmalek
Liver Transplant, Liver Transplantation
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
The primary aim of this study is to determine whether a peripheral blood or graft lymphocyte phenotype of immune senescence or exhaustion is different between operationally tolerant and non-tolerant liver allograft recipients.
- Trial name
- OPTIMAL (NCT02533180)
- Testing
- Immunosuppression withdrawal
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)